Compare RNAZ & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RNAZ | BEAT |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.9M | 22.7M |
| IPO Year | 2021 | 2021 |
| Metric | RNAZ | BEAT |
|---|---|---|
| Price | $1.40 | $0.37 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $3.13 |
| AVG Volume (30 Days) | 17.7K | ★ 1.1M |
| Earning Date | 08-14-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 15.07 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,197.12 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.30 | $0.36 |
| 52 Week High | $12.60 | $4.00 |
| Indicator | RNAZ | BEAT |
|---|---|---|
| Relative Strength Index (RSI) | 31.10 | 40.42 |
| Support Level | N/A | N/A |
| Resistance Level | $1.93 | $0.52 |
| Average True Range (ATR) | 0.15 | 0.05 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 0.00 | 1.41 |
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.
HeartBeam Inc is a medical technology company focused on developing higher resolution ambulatory electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The company's proprietary and patented technology platform captures the heart's electrical activity from three dimensions and synthesizes a 12-lead ECG from these signals. The company has received U.S. Food and Drug Administration (FDA) clearance for its ECG solutions.